Cylembio (imsapepimut and etimupepimut, adjuvanted), an off-the-shelf therapeutic cancer vaccine, plus pembrolizumab narrowly missed on its primary endpoint of progression free survival for patients with unresectable or metastatic melanoma, according to phase III trial results.
For years, personalized cancer vaccines have promised to make a radical idea possible—a treatment designed not just for a particular type of cancer, but for the distinctive mutations in a patient’s tumor.
